Alirocumab (anti-PCSK9) |
Catalog No.GC65044 |
알리로쿠맙(항-PCSK9)은 전단백 전환효소 서브틸리신/켁신 9형(PCSK9)을 억제하는 인간 단일클론 항체입니다.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1245916-14-6
Sample solution is provided at 25 µL, 10mM.
Alirocumab (anti-PCSK9) is a human monoclonal antibody inhibiting proprotein convertase subtilisin/kexin type 9 (PCSK9). Alirocumab specifically binds PCSK9, a down regulator of liver low-density lipoprotein (LDL)-receptors, thereby increasing the ability of the liver to bind LDL-cholesterol (LDL-C) and reducing levels of LDL-C in blood. Alirocumab can be used for the research of hypercholesterolemia[1][2].
[1]. Markham A. Alirocumab: First Global Approval. Drugs. 2015;75(14):1699-1705.
[2]. Tavori H, et al. Alirocumab: PCSK9 inhibitor for LDL cholesterol reduction. Expert Rev Cardiovasc Ther. 2014 Oct;12(10):1137-44.
Average Rating: 5
(Based on Reviews and 30 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *